Thyroid Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Thyroid Cancer – Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Thyroid Cancer
- The report reviews pipeline therapeutics for Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thyroid Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Aadi Bioscience IncAdvenchen Laboratories LLC
AffyImmune Therapeutics Inc
Akeso Inc
Akiram Therapeutics
Alphamab Oncology
Aminex Therapeutics Inc
Applied Pharmaceutical Science Inc
Arch Oncology Inc
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Bio-Thera Solutions Ltd
BioMed Valley Discoveries Inc
Biovista Inc
Black Diamond Therapeutics Inc
Boston Children's Hospital
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
C4 Therapeutics Inc
CAS-Lamvac Biotech Co Ltd
Cello Therapeutics Inc
Centrose LLC
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Codiak BioSciences Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Duality Biologics (Shanghai) Co Ltd
Eisai Co Ltd
Ellipses Pharma Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Full-Life Technologies Ltd
Genelux Corp
Gilead Sciences Inc
Gradalis Inc
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HEC Pharma Co Ltd
Heilongjiang ZBD Pharmaceutical Co Ltd
Helsinn Healthcare SA
Hutchison MediPharma Ltd
Ikena Oncology Inc
ImmunityBio Inc
ImmunoForge Co Ltd
Immunome Inc
IngenoVax LLC
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Intensity Therapeutics Inc
Iovance Biotherapeutics Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd
Johnson & Johnson
Juntendo University Hospital
KinaRx LLC
Kinnate Biopharma Inc
Kite Pharma Inc
KLUS Pharma Inc
Kura Oncology Inc
LeadArtis SL
Lotus Pharmaceutical Co Ltd
Loxo Oncology Inc
MedGene Therapeutics Inc
Merck & Co Inc
Mersana Therapeutics Inc
Minghui Pharmaceutical (Shanghai) Co Ltd
Molecular Targeting Technologies Inc
Novartis AG
Nuvalent Inc
Ohio State University
Ono Pharmaceutical Co Ltd
Osaka University
Perspective Therapeutics Inc
Pfizer Inc
Plexxikon Inc
Plus Therapeutics Inc
Public Univeristy Hospital of Pisana
Purple Biotech Ltd
Pyxis Oncology Inc
Recordati SpA
Regeneron Pharmaceuticals Inc
Release Therapeutics
RemeGen Co Ltd
Revolution Medicines Inc
Salubris Biotherapeutics Inc
Savoy Pharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Jiao Tong University School of Medicine
Shenzhen Xiankangda Life Sciences Co Ltd
Shouyao Holding Co Ltd
Sichuan University
Sichuan Yingrui Pharmaceutical Technology Co Ltd
SOTIO Biotech AS
SpringWorks Therapeutics Inc
Suzhou SmartNuclide Biopharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Synactix Pharmaceuticals Inc
Theratechnologies Inc
Thryv Therapeutics Inc
Tiziana Life Sciences Plc
TransThera Sciences (Nanjing) Inc
Trophogen Inc
TYK Medicines Inc
Tyme Inc
Tyra Biosciences Inc
UBI Pharma Inc
UbiVac Inc
University of Arkansas for Medical Sciences
University of Florida
University of Pisa
Verastem Inc
Visionary Pharmaceuticals Inc
Xencor Inc
Xiangxue Life Sciences
Xynomic Pharmaceuticals Holdings Inc
Y-Biologics Inc
YaoPharma Co Ltd